

## Special Issue

# Colorectal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches

### Message from the Guest Editors

Colorectal cancer (CRC) is the third most diagnosed cancer and a leading cause of cancer-related death worldwide. For the past several decades, significant progress in its molecular pathogenesis has led to precise treatment and patient management. Knowledge regarding pathogenesis of colorectal cancer has grown, but it is still limited. Understanding the underlying molecular mechanisms of CRC is essential to improve early diagnosis and patient-tailored treatment. Furthermore, the unique clinicopathologic features and risk factors of CRC are not well defined yet. There is an urgent need to clarify clinical features and risk factors different from another GI tract malignancy to implement specific screening and management strategies. Especially, in this Special Issue, we would like to deal with the management of relatively rare conditions of CRC such as obstructive colon and rectal cancer, lateral pelvic lymph node metastasis from rectal cancer, early-onset (young age) CRC, and quality of life in CRC survivorships. In this Special Issue, articles with a focus on the molecular biology, biomarkers, clinicopathologic characteristics, risk factors, and treatment strategies are invited.

### Guest Editors

Dr. Bong-hyeon Kye

Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea, 93-1, Jungbu-daero, Paldal-gu, Suwon-si 16247, Gyeonggi-do, Korea

Dr. Ri Na Yoo

Division of Colorectal Surgery, Department of Surgery, St. Vincent Hospital, The Catholic University of Korea 93-6, Ji-dong, Paldal-gu, Suwon 442-723, Gyeonggi-do, Korea

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/111041](https://mdpi.com/si/111041)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).